JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.45 -0.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.45

Max

21.45

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -21M
Pardavimai	14M 54M
Pelno marža	-39.611
Darbuotojai	178
EBITDA	-3.8M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-3.62% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.2B
Ankstesnė atidarymo kaina	21.68
Ankstesnė uždarymo kaina	21.45

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-30 23:08; UTC

Uždarbis

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 23:07; UTC

Uždarbis

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 22:20; UTC

Uždarbis

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

2026-04-30 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026-04-30 23:47; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-30 23:47; UTC

Rinkos pokalbiai

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

2026-04-30 23:27; UTC

Rinkos pokalbiai

Liontown Lithium Recovery Expected to Improve -- Market Talk

2026-04-30 23:22; UTC

Uždarbis

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

2026-04-30 23:20; UTC

Rinkos pokalbiai

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

2026-04-30 22:52; UTC

Uždarbis

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 22:33; UTC

Uždarbis

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

2026-04-30 22:32; UTC

Uždarbis

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

2026-04-30 22:32; UTC

Uždarbis

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

2026-04-30 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

2026-04-30 22:11; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-30 22:11; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-30 22:11; UTC

Rinkos pokalbiai

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

2026-04-30 22:05; UTC

Uždarbis

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

2026-04-30 21:57; UTC

Uždarbis

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

2026-04-30 21:56; UTC

Uždarbis

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

2026-04-30 21:56; UTC

Uždarbis

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

2026-04-30 21:55; UTC

Uždarbis

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

2026-04-30 21:54; UTC

Uždarbis

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

2026-04-30 21:54; UTC

Uždarbis

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

2026-04-30 21:53; UTC

Uždarbis

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

2026-04-30 21:49; UTC

Uždarbis

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

2026-04-30 21:49; UTC

Uždarbis

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-3.62% į apačią

12 mėnesių prognozė

Vidutinis 20.75 USD -3.62%

Aukščiausias 21.5 USD

Žemiausias 17 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.